Home・Список акций・Coherus Oncology Inc

Coherus Oncology Inc

Открыт

СекторЗдравоохранение

1.44 7.46

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.33

Макс.

1.37

Ключевые показатели
By Trading Economics
Доход	-21M -59M
Продажи	2M 14M
P/E Средняя по отрасли	3.509 57.366
Прибыль на акцию	-0.22
Рентабельность продаж	-412.092
Сотрудники	144
EBITDA	3.7M -30M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+465.69% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-12M 210M
Предыдущая цена открытия	-6.02
Предыдущая цена закрытия	1.44

Новостные настроения

By Acuity

100%

329 / 340 Рейтинг в Healthcare

Coherus Oncology Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

25 авг. 2026 г., 20:07 UTC

Coherus Oncology Inc. shares are trading roughly flat amid easing Treasury yields, which typically support equities and enhance investor sentiment toward risk assets.

24 авг. 2026 г., 20:04 UTC

Coherus Oncology Inc shares are lower today, continuing a broader market decline. No specific company news has been identified to explain the movement.

21 авг. 2026 г., 20:01 UTC

Correlated Moves

Coherus BioSciences Inc. shares are higher today, reflecting positive momentum in the biotechnology sector and broader trends in related equities since Thursday's close.

20 авг. 2026 г., 23:16 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting modest gains despite broader market pressures and no specific company news identified.

19 авг. 2026 г., 20:02 UTC

Coherus BioSciences remains roughly flat during Wednesday's session, with no specific news identified. The broader market also showed little change.

18 авг. 2026 г., 23:26 UTC

Coherus BioSciences Inc is trading higher in after-market hours, despite broader market pressures from rising bond yields and elevated oil prices.

17 авг. 2026 г., 23:41 UTC

News

Coherus BioSciences announced a special dividend of contingent value rights, boosting shares in after-market trading following the company's strategic asset sale initiative.

14 авг. 2026 г., 19:31 UTC

Coherus BioSciences Inc shares are higher today, despite no specific news. Broader market sentiment includes concerns over disappointing U.S. retail sales data.

13 авг. 2026 г., 19:46 UTC

Social Media

Coherus BioSciences Inc shares are lower, extending a four-session decline. Despite social media optimism, the stock remains below its 20-day moving average.

12 авг. 2026 г., 23:01 UTC

Coherus BioSciences Inc shares are trading higher in after-market hours, despite recent declines and no specific news to explain the movement.

11 авг. 2026 г., 19:36 UTC

Coherus BioSciences Inc shares are lower amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports. No specific company news identified.

10 авг. 2026 г., 23:31 UTC

Coherus BioSciences Inc shares are higher in after-market trading, advancing from a low of 0.81% to a high of 3.25% since Monday's close.

8 авг. 2026 г., 00:01 UTC

Coherus BioSciences Inc shares rose in after-market hours, recovering from earlier volatility and settling higher since Friday's close despite no specific news identified.

7 авг. 2026 г., 23:21 UTC

Coherus BioSciences Inc shares are rising in after-market trading, following a Labor Department report that reduced expectations for a Federal Reserve rate hike.

6 авг. 2026 г., 23:21 UTC

Coherus BioSciences Inc shares fell in after-market trading, reflecting ongoing weakness and volatility amid a lack of specific news to explain the decline.

5 авг. 2026 г., 23:01 UTC

News

Coherus BioSciences shares are lower in after-market trading following a second-quarter adjusted EPS of -$0.19, despite exceeding estimates. Sales missed expectations at $14.31 million.

4 авг. 2026 г., 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

3 авг. 2026 г., 19:44 UTC

Coherus BioSciences Inc shares are higher during Monday's session, continuing a notable advance since Friday's close, despite trading below its 20-day moving average.

31 июл. 2026 г., 20:06 UTC

Coherus BioSciences shares are lower today, amid rising U.S. Treasury yields and crude oil prices, which have heightened inflation concerns and interest rate expectations.

30 июл. 2026 г., 22:46 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting a positive response amid broader market recovery despite no specific company news identified.

29 июл. 2026 г., 18:46 UTC

Macro Event

Coherus BioSciences Inc shares are lower today amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

27 июл. 2026 г., 17:31 UTC

Coherus BioSciences Inc shares are higher during Monday's session, reflecting broader market trends amid declining oil prices that have eased inflation concerns.

23 июл. 2026 г., 19:56 UTC

Coherus BioSciences Inc is trading lower amid broader market concerns over corporate earnings and inflation pressures. Shares remain below their 20-day moving average.

22 июл. 2026 г., 18:26 UTC

Coherus BioSciences Inc shares are trading lower amid broader market pressures, remaining near the lower end of their one-month range. No specific news was identified.

21 июл. 2026 г., 19:41 UTC

Social Media

Coherus BioSciences Inc shares are higher as analysts set a $7 average price target, with potential for positive data readouts this month.

20 июл. 2026 г., 17:31 UTC

Coherus BioSciences Inc. shares are roughly flat today, showing little change since Friday's close amid routine trading activity within a one-month range.

Сравнение c конкурентами

Изменение цены

Coherus Oncology Inc Прогноз

Целевая цена

By TipRanks

465.69% рост

Прогноз на 12 месяцев

Средняя 7.75 USD 465.69%

Максимум 10 USD

Минимум 4 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Coherus Oncology Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

Покупка

Удержание

Продажа

Основано на мнении 5 аналитиков, присваивавших рейтинги акциям Coherus Oncology Inc – Данные за последние 3 месяца.

Настроения

By Acuity

329 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.